Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated AR‐Vs require a f...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yukiyoshi Hirayama, Teresa Tam, Kunzhong Jian, Raymond J. Andersen, Marianne D. Sadar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2020-10-01
Edice:	Molecular Oncology
Témata:	androgen receptor AR‐V7 combination therapy CRPC EPI‐002 ralaniten
On-line přístup:	https://doi.org/10.1002/1878-0261.12770
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!